Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Dynavax Surges after FDA Reverses Opinion

By Pharmaceutical Processing | July 29, 2011

NEW YORK (AP) — Shares of Dynavax Technologies Corp. jumped Thursday after
the company said regulators agreed the company demonstrated the consistency of
its experimental hepatitis B vaccine Heplisav in a recent clinical trial.

Dynavax said the Food and Drug Administration’s Center for Biologics
Evaluation and Research agreed the study proved the company can make consistent
batches of Heplisav.

On July 20, the company said Heplisav did not meet one of its “consistency”
goals in the study because one production lot had higher concentrations of
antibodies than the others after eight weeks. Dynavax stock plunged 19 percent
that day.

At the time, the company said Heplisav did meet the consistency criteria at
other points in the study. It said Thursday that the FDA
accepted that reasoning. Dynavax said it still plans to file for FDA approval of Heplisav later this year for use in patients
who do not respond to other therapies.

Shares of the Berkeley, Calif., company rose 57 cents, or 23.5 percent, to $3
in afternoon trading.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE